Jazz Pharmaceuticals plc (Nasdaq: JAZZ)

https://www.jazzpharma.com

Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain, psychiatry and women's health. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate), Erwinaze™ (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide intrathecal infusion), FazaClo® (clozapine USP) HD and LD, Luvox CR® (fluvoxamine maleate) and Elestrin® (estradiol gel 0.06%). Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by an international division, EUSA Pharma. *

	Start	2012-06-12 existent
	Industry	pharmaceutical
	Person	Cozadd, Bruce (Jazz Pharmaceuticals 201312 CEO)

	Region	Dublin
	Country	Ireland, Republic of
	Street	One Burlington Road Fourth Floor, Connaught House
	City	Dublin 4
	Tel	+353-1-634-7800
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2023-11-16

More documents for Jazz Pharmaceuticals plc (Nasdaq: JAZZ)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]